Omeros Co. (NASDAQ:OMER) Shares Acquired by Barclays PLC

Barclays PLC increased its stake in shares of Omeros Co. (NASDAQ:OMER) by 121.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 94,640 shares of the biopharmaceutical company’s stock after purchasing an additional 51,873 shares during the quarter. Barclays PLC owned 0.16% of Omeros worth $376,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Wellington Management Group LLP acquired a new stake in shares of Omeros in the 3rd quarter worth $305,000. Bank of New York Mellon Corp raised its holdings in Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Omeros in the second quarter valued at about $105,000. SG Americas Securities LLC purchased a new stake in Omeros in the 3rd quarter valued at approximately $80,000. Finally, SPC Financial Inc. acquired a new position in Omeros during the 3rd quarter worth approximately $77,000. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

OMER has been the subject of several recent analyst reports. Rodman & Renshaw initiated coverage on Omeros in a report on Thursday, November 14th. They issued a “buy” rating and a $9.00 price target for the company. StockNews.com raised Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Finally, Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Omeros presently has an average rating of “Moderate Buy” and an average target price of $22.50.

Omeros Trading Up 13.9 %

Shares of NASDAQ OMER opened at $11.21 on Friday. The company’s 50-day moving average price is $8.32 and its 200 day moving average price is $5.62. Omeros Co. has a 52 week low of $2.61 and a 52 week high of $13.60. The stock has a market cap of $649.62 million, a price-to-earnings ratio of -4.85 and a beta of 1.97.

Omeros Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.